Zevra Therapeutics heads into its September-quarter report with a split personality. Its US rare disease franchise is producing the cleanest numbers in the company's history, yet the stock has been sliding as the European path for arimoclomol turned from routine to uncertain. The upcoming release will show whether US commercial strength can carry the story while the EU question stays open.
Wall Street is looking for earnings of $0.14 per share on revenue of about $36.7 million. Against a year-ago quarter of $26.1 million in revenue and a loss of a penny per share, that is 41% top-line growth. The roughly 1,500% EPS growth figure mostly reflects how low the starting point was. The more telling detail is sequential. Consensus sits below the $39.7 million and $0.25 per share Zevra posted last quarter, so analysts are already allowing for a step back. Management has not issued formal guidance, so the Street is effectively setting the bar on its own. That cushion matters because a quarter that simply holds revenue near last quarter's level would clear expectations comfortably.
The logic behind the cautious estimate comes from the last call. US MyPlyfa net sales jumped 23% sequentially to $30.2 million, helped partly by channel inventory being rebuilt to target after falling below range in the prior quarter. Some of that lift may not repeat. Expanded access reimbursement is the other wild card. It came in at $9.0 million after $10.2 million the quarter before, and management acknowledged that ordering outside the steady French program is hard to predict. A US figure at or above $30 million would suggest the gain reflected genuine patient demand rather than restocking. A drop back toward the mid-$20 million range would raise questions about how much of last quarter was timing.
The leading indicators deserve as much attention as revenue. Cumulative enrollment forms reached 184, but quarterly additions have cooled from 24 at the late-2025 peak to 9 and then 14. Payer covered lives have stalled at 69%. Updated NPC treatment guidelines that endorse combination therapy including MyPlyfa should, in theory, restart enrollment growth. A quarter with new forms back in the high teens or 20s, plus some movement in coverage, would support the idea that the guideline change is broadening the prescriber base. Another quarter in the single digits or low teens would suggest the readily identifiable patients have largely been found.
The pipeline adds to the risk. The negative CHMP opinion moved arimoclomol into a 120-day re-examination with new rapporteurs and an advisory group meeting, and an opinion is expected in the fourth quarter. Any commentary on how that process is going will be closely parsed. The soliprolol program for vascular Ehlers-Danlos syndrome has logged only 3 of 28 required events, so details on the promised FDA re-engagement in the second half could matter as much as the quarter's numbers. On the positive side, the Orange Book listing that extends US protection to 2041 and a debt-free balance sheet with $260.2 million in cash give Zevra room to absorb setbacks.
The market has not been patient. Shares are down nearly 16% since the last report while the S&P 500 was essentially flat. At $9.53, the stock trades below its 200-day moving average of $10.71 and has slipped under its post-earnings low of $9.76. Sentiment is slightly bearish, little changed from last quarter. Expectations look subdued, and that could work in Zevra's favor. The central issue is whether US MyPlyfa demand, as measured by sales durability and renewed enrollment growth, is strong enough to stand on its own if Europe does not come through.